💊scientific experiment protocol
Pump.Science Longevity Testing Protocol (Simple Overview)
This document explains our three‑stage pipeline for evaluating compounds that may extend lifespan and improve healthspan. Each stage builds on the previous one, starting with short‑lived invertebrates and progressing to mammals.
Stage 1 – C. elegans Lifespan Assay
Contract Lab
Ora Biomedical
Model Organism
Caenorhabditis elegans (wild‑type N2)
Group Size
60 worms / compound vs 60 worms / vehicle control
Primary Endpoint
Median & maximum lifespan
Runtime
Up to 8 weeks (culture → final death event)
Data Delivery
Experiment is run first; full video & data are streamed retrospectively once complete
Why this matters C. elegans provide a rapid first screen for pro‑longevity effects before investing in more complex organisms.
Stage 2 – Drosophila (Fly) Health & Lifespan Assay
Contract Lab
Tracked Biotechnologies
Model Organism
Drosophila melanogaster
Group Size
30 flies / compound vs 30 flies / control
Primary Endpoints
• Lifespan• Movement metrics (speed & total distance)• Negative geotaxis (climbing latency)
Lead Time
≈ 10 days to culture and load arenas
Runtime
≈ 70 days total
Data Delivery
Continuous live‑streaming video + rolling data uploads
Why this matters Motor performance (geotaxis) and spontaneous activity act as surrogates for overall health, revealing functional benefits beyond survival alone.
Stage 3 – Mouse Lifespan & Functional Assay
Contract Lab
VivoArchitect
Model Organism
C57BL/6 mice
Group Size
20 mice / compound vs 20 mice / control
Primary Endpoint
Overall survival (lifespan)
Supplementary Tests*
Open Field, Rotarod, Y‑Maze, Elevated Plus Maze, Hanging Test, Grip Strength, Automated Gender Recognition
Health Monitoring
Body weight, rectal temperature, CBC, plasma safety biomarkers
Sourcing
Mice purchased from licensed SPF vendor (C57BL/6, 6‑8 weeks old)
*Functional assays are selected case‑by‑case, driven by the compound’s proposed mechanism.
Stage 4 – Human Wearable‑Based Double‑Blind Study
Study Type
Randomised, placebo‑controlled, double‑blind
Participants
~30 healthy adults per arm (exact N defined per protocol)
Primary Endpoints
Wearable‑derived endpoints, i.e. VO₂max, resting heart rate, sleep efficiency, etc.
Secondary Endpoints
Heart‑rate variability, activity level, other validated wearable biomarkers
Runtime
12 weeks
Data Delivery
De‑identified wearable data streamed to an open dashboard in near‑real time
Why this matters Human data confirms translatability and identifies early signals of safety & efficacy before larger trials.
Compound Dosing – Dosing regimens are set in consultation with each CRO and compound submitter.
For detailed, peer‑reviewable methodology, refer to our preprint
Last updated: 2025‑07‑06
Last updated